전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved667 programs
AntibodyLimited DatastaleCancer Research UKPhase 2

atezolizumab (Tecentriq, HTL0039732 Capsules and atezolizumab infusion)

Neoplasms; Prostatic Neoplasms, Castration-Resistant · Neoplasms

#Neoplasms#Antibody#Phase2#monoclonal-antibody#ProstaticNeoplasms+2
Trials 1Status Recruiting
AntibodyLimited DatastaleTaizhou Hanzhong biomedical co.…Phase 3

Pucotenlimab (HX008, HX008(Pucotenlimab))

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase3#monoclonal-antibody#Taizhou
Trials 1Status Recruiting
AntibodyLimited DatastaleShuhong YiPhase 2

atezolizumab (Tecentriq, Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab)

Recurrent Liver Cancer After Liver Transplantation · Recurrent Liver Cancer After Liver Trans

#RecurrentLiverCancerAfterLiverTr#Antibody#Phase2#monoclonal-antibody#Shuhong
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

trastuzuamb (Herceptin, Herceptin (trastuzuamb))

HER2 Positive Early or Locally Advanced Breast Cancer · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#HER2PositiveEarlyorLocallyAdvanc+1
Trials 1Status Active
CGTLimited DatastaleNingbo Cancer HospitalPhase 2

HerinCAR-PD1 cells (HerinCAR-PD1 cells)

PD-1 Antibody; CAR-T Cells · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Hunan
Trials 1Status Active
AntibodyLimited DatastaleShanghai Pulmonary Hospital, Sh…Phase 2

IBI310+Sintilimab (IBI310+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Shanghai
Trials 1Status Recruiting
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 + nivolumab)

Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#HeadandNeckCancer+1
Trials 1Status Discontinued
ADCLimited DatastaleIksuda Therapeutics Ltd.Phase 1

IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody (IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody)

Colorectal Cancer; Gastro Esophageal Junctional Cancer · Colorectal Cancer

#ColorectalCancer#ADC#Phase1#antibody-drug-conjugate#GastroEsophagealJunctionalCancer+1
Trials 1Status Recruiting
CGTLimited DatastaleThe Methodist Hospital Research…Phase 2

IL-12 gene therapy (IL-12 gene therapy)

Triple Negative Breast Cancer; Anthracycline-refractory TNBC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleNational Institutes of Health C…Phase 2

IL-12 transduced TIL (IL-12 transduced TIL)

Skin Cancer; Metastatic Melanoma · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleGenovn Therapeutics (Suzhou) Co…Phase 1

IL-15 enhanced engineered NK cells (IL-15 enhanced engineered NK cells)

Solid Tumors; Metastatic Cancer · Solid Tumors

#SolidTumors#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of Colorado, DenverPhase 1

IPI-926 and Cetuximab (IPI-926 and Cetuximab)

Recurrent Head and Neck Cancer · Recurrent Head and Neck Cancer

#RecurrentHeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#University
Trials 1Status Active
CGTLimited DatastaleHunan Zhaotai Yongren Medical I…Phase 2

ITNK cell therapy (ITNK cell therapy)

Anti-cancer Cell Immunotherapy; T Cell and NK Cell · Anti-cancer Cell Immunotherapy

#Anti-cancerCellImmunotherapy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 3

Imprime PGG + cetuximab (Imprime PGG + cetuximab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#monoclonal-antibody#Eli
Trials 1Status Discontinued
CGTLimited DatastaleMemorial Sloan Kettering Cancer…Phase 1

Infusion of MCARH109 T cells (Infusion of MCARH109 T cells)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHospices Civils de LyonPhase 2

nivolumab (Opdivo, IP, Intraperitoneal, Intraperitoneal (IP) nivolumab infusion)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#monoclonal-antibody#Hospices
Trials 1Status Active
AntibodyLimited DatastaleShanghai Cancer Hospital, ChinaPhase 2

nivolumab (Opdivo, Intraventricular Nivolumab)

Leptomeningeal Metastasis · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#monoclonal-antibody#Shanghai
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 2

Investigational CAR-T (Investigational CAR-T)

Malignancy; Cancer · Malignancy

#Malignancy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued

21 / 34 pages

← PreviousNext →